Clinical evaluation of radio-labelled bleomycin for tumor detection

J.J. Rasker, H. Beekhuis, M.A.P.C. van de Poll, A. Versluis, H. Jurjens, M.G. Woldring

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram. Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution. Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals. We conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.

Original languageEnglish
Pages (from-to)238-248
Number of pages11
JournalNuklear Medizin - Isotope In Medizin und Biologie
Volume17
Issue number6
DOIs
Publication statusPublished - 1 Dec 1978
Externally publishedYes

Fingerprint

Bleomycin
Radio
Neoplasms
Radiopharmaceuticals
Normal Distribution
Radioisotopes
Bone and Bones
Pharmaceutical Preparations

Cite this

Rasker, J. J., Beekhuis, H., van de Poll, M. A. P. C., Versluis, A., Jurjens, H., & Woldring, M. G. (1978). Clinical evaluation of radio-labelled bleomycin for tumor detection. Nuklear Medizin - Isotope In Medizin und Biologie, 17(6), 238-248. https://doi.org/10.1055/s-0037-1620700
Rasker, J.J. ; Beekhuis, H. ; van de Poll, M.A.P.C. ; Versluis, A. ; Jurjens, H. ; Woldring, M.G. / Clinical evaluation of radio-labelled bleomycin for tumor detection. In: Nuklear Medizin - Isotope In Medizin und Biologie. 1978 ; Vol. 17, No. 6. pp. 238-248.
@article{f4e8cab38e23451a9c1ba9bbf75f5474,
title = "Clinical evaluation of radio-labelled bleomycin for tumor detection",
abstract = "Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram. Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution. Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals. We conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.",
author = "J.J. Rasker and H. Beekhuis and {van de Poll}, M.A.P.C. and A. Versluis and H. Jurjens and M.G. Woldring",
year = "1978",
month = "12",
day = "1",
doi = "10.1055/s-0037-1620700",
language = "English",
volume = "17",
pages = "238--248",
journal = "Nuklearmedizin",
issn = "0029-5566",
publisher = "Schattauer GmbH",
number = "6",

}

Rasker, JJ, Beekhuis, H, van de Poll, MAPC, Versluis, A, Jurjens, H & Woldring, MG 1978, 'Clinical evaluation of radio-labelled bleomycin for tumor detection', Nuklear Medizin - Isotope In Medizin und Biologie, vol. 17, no. 6, pp. 238-248. https://doi.org/10.1055/s-0037-1620700

Clinical evaluation of radio-labelled bleomycin for tumor detection. / Rasker, J.J.; Beekhuis, H.; van de Poll, M.A.P.C.; Versluis, A.; Jurjens, H.; Woldring, M.G.

In: Nuklear Medizin - Isotope In Medizin und Biologie, Vol. 17, No. 6, 01.12.1978, p. 238-248.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Clinical evaluation of radio-labelled bleomycin for tumor detection

AU - Rasker, J.J.

AU - Beekhuis, H.

AU - van de Poll, M.A.P.C.

AU - Versluis, A.

AU - Jurjens, H.

AU - Woldring, M.G.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram. Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution. Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals. We conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.

AB - Investigations with bleomycin labelled with radionuclides other than 57Co in patients with cancer and in tumor-bearing animals are described. In patients 57Co-bleo appears to be a better tumor-seeking radiopharmaceutical than 111In-bleo, 99mTc-bleo or 197Hg-bleo. This can be explained by a higher stability in vivo and a better tumor-seeking property of 57Co-bleo and less disturbing activity in the cardiac pool and in bone and other normal tissues when assessing the scintigram. Results with 111In-bleo labelled in acidic solution are not essentially different from those with 111In-bleo labelled in neutral solution. Results of 197Hg-bleo are almost identical with those of 197HgCl2 regarding the tumor-seeking effect as well as the distribution in normal tissues and organs. Probably the complex of 197Hg to bleomycin is not stable in vivo. The superiority of 57Co-bleo over 99mTc-bleo and also over 67Cu-bleo is confirmed by experiments on tumor bearing animals. We conclude that the indication for use of bleomycin as a tumor-seeking pharmaceutical labelled with 111In, 99mTc, 197Hg or 67Cu seems to be very limited.

UR - http://www.scopus.com/inward/record.url?scp=0018216942&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1620700

DO - 10.1055/s-0037-1620700

M3 - Article

C2 - 84374

AN - SCOPUS:0018216942

VL - 17

SP - 238

EP - 248

JO - Nuklearmedizin

JF - Nuklearmedizin

SN - 0029-5566

IS - 6

ER -